doi: 10.1038/s41467-018-05470-4 59 ShyuJFLiuWCZhengCMFangTCHouYCChangCTet al
If youre ready for care that meets you where you are and moves you forward one wise choice at a time, reach out
However, its use beyond this approved indication, such as for erectile dysfunction in men, is considered off-label
The choice is clear: Should GLP-1 originators maintain a dual-brand strategy, which allows for premium pricing in the self-pay weight management segment while enabling reimbursement for Type 2 diabetes, but also requires greater investment in brand differentiation and market education
"However, I would be careful to draw conclusions solely based on this study."
NICEs 2024 technology appraisal on tirzepatide says the clinical evidence suggests tirzepatide is more effective overall for managing overweight and obesity than semaglutide and diet-and-exercise support alone